Orellana R.,University of Santiago de Chile |
Orellana R.,Biomedical Research Consortium of Chile |
Kato S.,University of Santiago de Chile |
Kato S.,Biomedical Research Consortium of Chile |
And 30 more authors.
BMC Cancer | Year: 2015
Background: An increase in circulating platelets, or thrombocytosis, is recognized as an independent risk factor of bad prognosis and metastasis in patients with ovarian cancer; however the complex role of platelets in tumor progression has not been fully elucidated. Platelet activation has been associated with an epithelial to mesenchymal transition (EMT), while Tissue Factor (TF) protein expression by cancer cells has been shown to correlate with hypercoagulable state and metastasis. The aim of this work was to determine the effect of platelet-cancer cell interaction on TF and "Metastasis Initiating Cell (MIC)" marker levels and migration in ovarian cancer cell lines and cancer cells isolated from the ascetic fluid of ovarian cancer patients. Methods: With informed patient consent, ascitic fluid isolated ovarian cancer cells, cell lines and ovarian cancer spheres were co-cultivated with human platelets. TF, EMT and stem cell marker levels were determined by Western blotting, flow cytometry and RT-PCR. Cancer cell migration was determined by Boyden chambers and the scratch assay. Results: The co-culture of patient-derived ovarian cancer cells with platelets causes: 1) a phenotypic change in cancer cells, 2) chemoattraction and cancer cell migration, 3) induced MIC markers (EMT/stemness), 3) increased sphere formation and 4) increased TF protein levels and activity. Conclusions: We present the first evidence that platelets act as chemoattractants to cancer cells. Furthermore, platelets promote the formation of ovarian cancer spheres that express MIC markers and the metastatic protein TF. Our results suggest that platelet-cancer cell interaction plays a role in the formation of metastatic foci. © 2015 Orellana et al.; licensee BioMed Central.
Pinto M.P.,University of Santiago de Chile |
Sotomayor P.,Andrés Bello University |
Carrasco-Avino G.,University of Chile |
Corvalan A.H.,University of Santiago de Chile |
And 4 more authors.
International Journal of Molecular Sciences | Year: 2016
Tumor angiogenesis is widely recognized as one of the "hallmarks of cancer". Consequently, during the last decades the development and testing of commercial angiogenic inhibitors has been a central focus for both basic and clinical cancer research. While antiangiogenic drugs are now incorporated into standard clinical practice, as with all cancer therapies, tumors can eventually become resistant by employing a variety of strategies to receive nutrients and oxygen in the event of therapeutic assault. Herein, we concentrate and review in detail three of the principal mechanisms of antiangiogenic therapy escape: (1) upregulation of compensatory/alternative pathways for angiogenesis; (2) vasculogenic mimicry; and (3) vessel co-option. We suggest that an understanding of how a cancer cell adapts to antiangiogenic therapy may also parallel the mechanisms employed in the bourgeoning tumor and isolated metastatic cells delivering responsible for residual disease. Finally, we speculate on strategies to adapt antiangiogenic therapy for future clinical uses. © 2016 by the authors; licensee MDPI, Basel, Switzerland.
Villavicencio A.,University of Chile |
Aguilar G.,University of Michigan |
Acua J.,University of Chile |
Gabler F.,University of Chile |
And 6 more authors.
International Journal of Obesity | Year: 2012
Enhanced endometrial proliferation correlates obesity to type-I (estrogen-dependent) endometrial cancer (EC). Our aim was to distinguish obese women (without EC) with differing endometrial proliferation. Endometrial and blood samples were obtained from normal-weight and obese women without EC. Type-I EC samples were obtained from obese patients. On measuring endometrial proliferation (Ki67 and phosphorylated histone H3 (p-H3)), two groups of obese women without EC were identified: obeseHigh Proliferating (O HP) and obeseLow Proliferating (OLP). Increased Ki67 (88.5%, P<0.001), p-H3 (62.6%, P<0.01), 17Β-estradiol/ progesterone ratio (46.3%, P<0.01) and endometrial estrogen receptor alpha (ERα) (82.2%, P<0.001) were observed in OHP compared with OLP patients. ECs possessed similar ERα and enhanced proliferation as OHP, suggesting that OHP women are at higher risk of type-I EC. OLP women were indistinguishable from normal-weight women regarding these determinants of endometrial proliferation, ERα and 17Β-estradiol/progesterone ratio. Our data may further define the obesity phenotype in regards to type-I EC risk and may help identify obese women more susceptible to develop type-I EC, allowing early intervention and a potential reduction in mortality. © 2012 Macmillan Publishers Limited All rights reserved.
In vitro cell response to chemotherapeutic agents, to personalize ovarian cancer treatment. Report of two cases [Potencial herramienta en la personalización del tratamiento oncológico. Casos clínicos]
Ibanez C. C.,University of Santiago de Chile |
Garrido S. M.,University of Santiago de Chile |
Medina L.,University of Santiago de Chile |
Kato S.,University of Santiago de Chile |
And 10 more authors.
Revista Medica de Chile | Year: 2013
Our laboratory has implemented an in vitro assay to estimate the response to chemotherapy in ovarian cancer cells pertaining to individual patients. In two selected patients, we determined the correlation between an in vitro assay of cells from suspected ovarian cancer ascites, with the clinical chemotherapy response. Cancer cells isolated from peritoneal fluid with suspected ovarian cancer were tested for cytotoxicity with corresponding chemotherapy regimens. Circulating Ca125 levels and attending physician consultation determined clinical course and response to chemotherapy. The in vitro assay result correlated with Ca125 levels, progression free survival and attending physician evaluation. The assay predicted correctly the failure of two successive chemotherapy regimes in the first patient, while predicting a favorable clinical response in the second subject.
Erices R.,University of Santiago de Chile |
Erices R.,Andrés Bello University |
Erices R.,Biomedical Research Consortium of Chile |
Bravo M.L.,University of Santiago de Chile |
And 19 more authors.
Reproductive Sciences | Year: 2013
The use of the type 2 diabetics drug metformin has been correlated with enhanced progression-free survival in ovarian cancer. The literature has speculated that this enhancement is due to the high concentration of metformin directly causing cancer cell death. However, this explanation does not fit with clinical data reporting that the women exposed to constant micromolar concentrations of metformin, as present in the treatment of diabetes, respond better to chemotherapy. Herein, our aim was to examine whether micromolar concentrations of metformin alone could bring about cancer cell death and whether micromolar metformin could increase the cytotoxic effect of commonly used chemotherapies in A2780 and SKOV3 cell lines and primary cultured cancer cells isolated from the peritoneal fluid of patients with advanced ovarian cancer. Our results in cell lines demonstrate that no significant loss of viability or change in cell cycle was observed with micromolar metformin alone; however, we observed cytotoxicity with micromolar metformin in combination with chemotherapy at concentrations where the chemotherapy alone produced no loss in viability. We demonstrate that previous exposure and maintenance of metformin in conjunction with carboplatin produces a synergistic enhancement in cytotoxicity of A2780 and SKOV3 cells (55% and 43%, respectively). Furthermore, in 5 (44%) of the 11 ovarian cancer primary cultures, micromolar metformin improved the cytotoxic response to carboplatin but not paclitaxel or doxorubicin. In conclusion, we present data that support the need for a clinical study to evaluate the adjuvant maintenance or prescription of currently approved doses of metformin during the chemotherapeutic treatment of ovarian cancer. © The Author(s) 2013.